Stay updated on Pembrolizumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Lymphoma Clinical Trial page.
Latest updates to the Pembrolizumab in Lymphoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe header now displays Revision: v3.3.2, replacing Revision: v3.3.1. No substantive study information is changed.SummaryDifference0.0%
- Check21 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check28 days agoChange DetectedThe funding lapse notice about government funding and NIH operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check43 days agoChange DetectedAdministrative updates are present, including a new last update date and posted results, while the core study design, arms, and eligibility remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check71 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference2%
- Check79 days agoChange DetectedUpdated version to v3.1.0; removed the term “Diffuse large b-cell lymphoma.”SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphoma Clinical Trial page.